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EDUCATIONAL INTERVENTION TO IMPROVE PATIENT 
UNDERSTANDING OF BREAST DENSITY 
KIMBERLY LISSETTE RIVERA 
ABSTRACT 
 Breast cancer is the most common cancer among women worldwide and has been 
a major public health concern for years. The main focus for improving breast cancer 
related outcomes has been on prevention and early detection. A mammogram, 2-D x-ray 
of the breasts, is the preferred screening tool for breast cancer. In the U.S., there is some 
controversy as to when screening mammograms should begin, however, all organizations 
agree that screening is important for prevention and early detection of breast cancer.  
In recent years there has been a question as to how effective mammograms are as 
a screening tool in women with dense breasts. Normal breast tissue is composed of 
fibrous, glandular, or adipose tissue. Dense breast is defined as the presence of large 
areas of fibrous or glandular tissue. The presence of fibrous and glandular tissue makes it 
more difficult to detect lesions due to lack of contrast. Dense breasts not only make it 
difficult to detect lesions but it is also in itself a risk factor for developing breast cancer.  
Given the difficulty in detecting lesions on mammogram and increased risk factor 
for breast cancer there has been a nationwide movement amongst advocacy groups to 
inform women of whether or not they have dense breasts. Many states have enacted 
legislation requiring that mammogram results include whether or not women have dense 
breasts. Current research has shown that although women may be more familiar with the 
term breast density, many are still not entirely show what breast density is and how it 
  vi 
relates to screening mammograms and breast cancer. In this proposed project we will 
focus on pre- and post-intervention questionnaire results following an educational 
intervention about breast density. The educational intervention will be a 45-minute 
lecture dividing into three sections: 1. General information about breast density 2. Breast 
Density and Breast Cancer 3. Supplemental Screening Recommendations. The 45-minute 
lecture will then be followed by a 15-minute question-answer period. This study will 
attempt to address the knowledge gap for women have received dense breast 
notifications.  
  
  vii 
TABLE OF CONTENTS 
 
TITLE……………………………………………………………………………………...i 
COPYRIGHT PAGE……………………………………………………………………...ii 
READER APPROVAL PAGE…………………………………………………………..iii 
ACKNOWLEDGMENTS ................................................................................................. iv 
ABSTRACT ........................................................................................................................ v 
TABLE OF CONTENTS .................................................................................................. vii 
LIST OF TABLES ............................................................................................................. ix 
LIST OF FIGURES ............................................................................................................ x 
LIST OF ABBREVIATIONS ............................................................................................ xi 
INTRODUCTION .............................................................................................................. 1 
Background ..................................................................................................................... 1 
Statement of the Problem ................................................................................................ 2 
Hypothesis....................................................................................................................... 3 
Objectives and specific aims ........................................................................................... 4 
REVIEW OF THE LITERATURE .................................................................................... 5 
Overview ......................................................................................................................... 5 
Existing research ........................................................................................................... 17 
METHODS ....................................................................................................................... 28 
  viii 
Study design .................................................................................................................. 28 
Study population and sampling ..................................................................................... 28 
Treatment (or intervention) ........................................................................................... 29 
Study variables and measures ....................................................................................... 30 
Recruitment ................................................................................................................... 31 
Data collection .............................................................................................................. 31 
Data analysis ................................................................................................................. 32 
Timeline and resources ................................................................................................. 33 
Institutional Review Board ........................................................................................... 34 
CONCLUSION ................................................................................................................. 35 
Discussion ..................................................................................................................... 35 
Summary ....................................................................................................................... 36 
Clinical and/or public health significance ..................................................................... 37 
LIST OF JOURNAL ABBREVIATIONS........................................................................ 38 
REFERENCES ................................................................................................................. 39 
CURRICULUM VITAE ................................................................................................... 44 
 
  
  ix 
LIST OF TABLES 
 
 
Table Title Page 
1 Molecular subtypes of Breast Cancer. Adapted from Dai 
et al. 
 
6 
2 BI-RADS Assessment and Management Categories. 
Adapted from ACR BI-RADS Atlas 2013 
 
11 
3 Breast Composition Categories Adapted from ACR BI-
RADS Atlas 2013 
 
11 
4 Tumor Prognostic Factors and Breast Density Category 
Adapted from Roubidoux et al 
 
14 
5 Tumor Stage and Breast Density Category Adapted from 
Roubidoux et al 
 
14 
6 Recall of notification content Adapted from Gunn 2018 24 
 
 
  
  x 
LIST OF FIGURES 
 
 
 
Figure Title Page 
1 Example of categories of breast density on mammogram 11 
   
   
   
   
   
 
 
  
  xi 
LIST OF ABBREVIATIONS 
 
ACR ................................................................................... American College of Radiology 
BCSC ..................................................................... Breast Cancer Surveillance Consortium 
BD .................................................................................................................. Breast Density 
BI-RADS..........................................................Breast Imaging-Reporting and Data System 
BMI ........................................................................................................... Body Mass Index 
BMC ................................................................................................. Boston Medical Center 
BSE ..................................................................Breast Imaging-Reporting and Data System 
CBE ..................................................................................................... Clinical Breast Exam 
DBN ............................................................................................. Dense Breast Notification 
DBT........................................................................................ Digital Breast Tomosynthesis 
DCIS .............................................................................................. Ductal carcinoma in situ 
ER ............................................................................................................ Estrogen Receptor 
HER2............................................................. Human Epidermal Growth Factor Receptor 2 
IDC ............................................................................................. Invasive Ductal Carcinoma  
ILC ........................................................................................... Invasive Lobular Carcinoma 
LCIS ............................................................................................Lobular Carcinoma In Situ 
MRI ........................................................................................ Magnetic Resonance Imaging 
NCCN ................................................................ National Comprehensive Cancer Network 
POMS-SF ...................................................................... Profile Of Mood States-Short Form 
PR ...................................................................................................... Progesterone Receptor 
TPB .......................................................................................... Theory of Planned Behavior 
  xii 
US ........................................................................................................................ Ultrasound 
USPSTF ........................................................United States Preventive Services Task Force 
 
 
 
 
 
 
 
 1 
INTRODUCTION 
Background 
Breast cancer is the most common cancer in women worldwide and continues to be a 
major public health concern.1  The World Health Organization estimates that nearly 2.1 
million are impacted each year and in 2018 breast cancer was responsible for an 
estimated 627,000 deaths.2 Given its impact on the public, it has been heavily studied and 
known risk factors include: age, BRCA1 or BRCA2 mutation, family history of breast 
cancer, chest radiation therapy, hormone replacement therapy, lifestyle behaviors, and 
dense breasts.2  
The main focus for improving breast cancer related outcomes has been on 
prevention and early detection. In the 1980s, the United States implemented screening 
guidelines that women between the ages of 40-74 should receive biennial mammograms, 
an x-ray of the breast.3,4 The goal of this was to detect lesions at an earlier stage. The 
implementation of breast screening has successfully decreased breast cancer related 
mortality by at least 20 percent.4  However, in recent years more attention has been 
placed on the effectiveness of mammograms as a screening tool in women who have 
dense breasts. 
Breasts are composed of 3 types of tissue: fibrous, glandular, and adipose tissue.5 
Adipose tissue appears dark on a mammogram, whereas fibrous and glandular tissue 
appear white. The three different types of tissue are normal findings on a mammogram. 
Dense breast is defined as having large areas of fibrous and glandular tissue present on a 
mammogram. The goal of a radiologist is to identify the lesions on a mammogram as 
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early as possible, however, when women have dense breast detecting lesions becomes 
more difficult. This is because fibrous tissue and glandular tissue appear white, similar to 
most breast cancer lesions.6 The presence of large areas of dense breast tissue can make it 
difficult to detect these lesions due to lack of contrast between the lesions and normal 
fibroglandular tissue. Dense breast tissue not only makes it difficult to detect lesions, but 
dense breast tissue in itself is an increased risk factor for breast cancer. Although dense 
breast tissue has been a known risk factor for breast cancer for women, few women are 
aware of this fact.7 
Statement of the Problem 
Women with extremely dense breast have a four to six time increased risk for breast 
cancer when compared to women with little or no fibroglandular tissue.8 Despite being a 
known risk factor, women are not aware of what dense breasts are nor that it increases the 
risk of getting breast cancer.7 
In recent years, breast density has gained significant attention through advocacy 
groups. The most notable activist was Nancy Capello, who was diagnosed with late stage 
breast cancer after being told she had a “normal” mammogram. She later discovered that 
she had dense breasts yet it was never communicated to her nor that its presence 
increased her risk for breast cancer.9 Due to growing dissatisfaction with the lack of 
complete communication about mammogram results, several states across the U.S have 
enacted dense breast notification (DBN) legislation. DBN legislation requires that a 
radiologist indicate the presence of dense breasts on a mammogram report.10 Although 
now the presence of dense breasts is being communicated to women, there is no 
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standardized memo for this notification. Despite the lack of a standardized memo for 
DBN, organizations such as the American College of Radiology have attempted to 
educate women about breast density by making a brochure to explain the topic.11 One 
other important factor to note and inform women about is that the assessment of breast 
density on mammogram is subjective. Radiologists estimate the amount of dense breast 
tissue present on mammogram and studies have found that there is a lot of variability 
among the readers.12 Techniques for automated breast density assessment have been 
developed but not in wide use currently.  
Many recent studies have found that, despite being told they have dense breasts, 
some women do not understand what dense breasts are nor do they realize it is a risk 
factor for breast cancer.13 The miscommunication and lack of complete explanation has 
also resulted in increased in anxiety among women.14  
 While many studies have analyzed the aftereffects of DBN legislation, no current 
study has attempted to implement methods to improve patient understanding. Despite this 
gap in research, a few studies have laid the groundwork by identifying key factors in 
improving patient understanding. For example, Gunn et al. conducted a study among 
women at a safety net hospital who identified they would prefer for their results to be 
communicated to them verbally using simple language along with visual images.13 
Hypothesis 
Implementing a 1-hour educational intervention for patients will result in increased 
knowledge and decreased anxiety surrounding their notification of having dense breasts.  
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Objectives and specific aims 
The main purpose of this study is to implement a patient educational intervention to 
increase patient understanding and comfort after receiving a dense breast notification. 
Patients from Boston Medical Center will be scheduled to participate in a 1-hour lecture 
about breast density. This will allow time for patient education and to address any 
questions the patient may have following completion of the lecture. This study has three 
specific aims: 
• To compare pre- and post-intervention scores of patient knowledge about dense 
breasts 
• To compare pre- and post-intervention scores of patient anxiety about dense 
breasts 
• To assess patient opinions of and suggestions for better educational intervention 
methods 
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REVIEW OF THE LITERATURE 
Overview 
Breast Cancer 
 
Breast cancer is the most common cancer in women worldwide.15 About 1 in 8 women in 
the United States will develop breast cancer over the course of their lifetime.16 Between 
2006 and 2015, breast cancer incidence increased by 0.4% per year.17 In 2019, it is 
estimated that there were will be 271,270 new cases of breast cancer. Breast cancer is the 
second most common cause of cancer death in women in the U.S. with about 42,260 
estimated deaths expected in 2019.  The death rate reached 33.2 per 100,000 in 1989 and 
has declined by 40% from 1989 to 2016 likely due to screening and better treatment 
options.18    
Risk factors for breast cancer can be divided into modifiable and non-modifiable 
factors. Modifiable risk factors include: weight, exercise, alcohol consumption, smoking, 
exposure to estrogen, recent oral contraceptive use, stress, and anxiety. Nonmodifiable 
risk factors include: female gender, older age, family history of breast cancer, personal 
history of breast cancer, race/ethnicity, radiation therapy to the face or chest, 
diethylstilbestrol exposure, and increased breast density.15 Among the numerous risk 
factors for breast cancer, older age and female gender are the strongest.17  
Breast cancer can be classified based on its invasiveness into surrounding tissue, 
as well as into molecular subtypes. Non-invasive breast cancer is a cancer that has not 
extended into tissue surrounding the lobule or ducts where the cancerous lesion 
originated.19 The two types of noninvasive breast cancer are ductal carcinoma in situ 
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(DCIS) and lobular carcinoma in situ (LCIS). Invasive breast cancer is when atypical 
cells have spread from the lobules or ducts into surrounding tissue. The different types of 
invasive cancer are: infiltrating lobular carcinoma (ILC), infiltrating ductal carcinoma 
(IDC), medullary carcinoma, mucinous carcinoma, and tubular carcinoma.19 Other rare 
forms of breast cancer include inflammatory breast cancer and Paget’s disease of the 
breast. Molecular subtypes of breast cancer include: luminal A, luminal B, HER2 over-
expression, triple-negative/basal-like, and normal-like (Table 1).20 The molecular 
subtypes of breast cancer are based on the genes the cancer expresses which include: ER, 
PR, HER2, and KI67.21 
 Table 1. Molecular subtypes of Breast Cancer. Adapted from Dai et al.20 
Molecular subtype Gene expression Prevalence 
Luminal A ER+, PR+, HER2-, 
KI67- 
23.7% 
Luminal B ER+, PR+, HER2-, 
KI67+ 
38.8% 
HER2 over-
expression 
ER-, PR-, HER2+ 11.2% 
Triple-
negative/Basal-like 
ER-, PR-, HER2-, 
basal marker + 
12.3% 
Normal-like ER+, PR+, HER2-, 
KI67- 
7.8% 
 
Treatment options for breast cancer range from local treatment to systemic 
treatment.22  Local treatment options include surgery or radiation, whereas systemic 
treatment options include chemotherapy, hormone therapy, and targeted therapy. Therapy 
is usually decided with a multidisciplinary team while taking molecular subtype, tumor 
invasiveness, and patient’s desires into consideration.23 Although there have been 
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improvements in treatment options and earlier detection, breast cancer still remains one 
of the top causes of cancer related deaths in women.16 
Breast Cancer screening  
Breast Cancer screening entails evaluating a woman’s breasts for malignancy before 
there are any clinical signs or symptoms of the disease.24 Methods of breast cancer 
screening include: clinical breast exam (CBE), breast self-examination (BSE), 
mammography, tomosynthesis, and magnetic resonance imaging.25 A CBE is a physical 
exam done by a trained healthcare provider.26 The sensitivity of CBE is 88% for lesions 
greater than 1 cm and between 34-44% for lesions smaller than 1 cm.25 BSE is when a 
woman examines her own breast visually and physically for any abnormalities.27  BSE 
has an overall sensitivity of 26 percent.25 Mammography is an x-ray of the breast and is 
the current recommended screening method by the United States Preventive Services 
Task Force (USPSTF).3 Tomosynthesis is a 3-D mammography in which the x-ray tube 
moves in an arc over the breast tissue. The Oslo Tomosynthesis Screening Trial 
demonstrated that the sensitivity for detecting lesions improved significantly from 54.1% 
to 70.5% when tomosynthesis was added as a screening method.28 MRI uses magnetic 
fields to produce cross-sectional images of the breast. Prior to capturing the images a 
contrast dye is injected in the vein to improve the quality and details in the image.29 The 
USPSTF and American Cancer Society recommend against teaching BSE.3,29 The 
USPSTF states that the current evidence for CBE and MRI is insufficient to assess 
benefits and harms of these additional screening methods. However, the American 
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Cancer Society no longer recommends CBE and they have recommended MRI screening 
for women with a high lifetime risk greater than 20 percent beginning at the age of 30.29  
Breast cancer screening with mammography became a widespread practice in the 
U.S. in the 1980s, which has resulted in a steady decrease in breast cancer mortality.4 
Randomized control trials have demonstrated that screening with mammography can 
decrease mortality by at least twenty percent.4 Screening guidelines for breast cancer 
were implemented in the hopes of detecting breast cancer at an earlier stage, which could 
allow for better treatment options and outcomes. Currently, there is controversary among 
various organizations as to when screening should begin and the frequency of 
screening.30 
The United States Preventive Services Task Force recommends that women 
between the ages of 50 to 74 years get a screening mammography every two years. For 
women between the ages of 40 to 49 the guidelines state that the decision to get a 
screening mammography should be discussed with a healthcare professional. The final 
decision to get a mammogram should always be an individual one based on the person’s 
preferences and risk factors.3 The UPSTSF does not recommend women between the 
ages of 40-49 with below average risk for breast cancer to get mammography. 
Mammography in this age group can lead to an increased number of false-positive results 
leading to unnecessary interventions. For example, a provider may biopsy or treat a 
cancer that would not have otherwise progressed or become apparent in that person’s 
lifetime.3 It is important to note that these recommendations are for asymptomatic women 
over the age of 40 who do not have the following risk factors: personal history of breast 
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cancer, previous history of high-risk breast lesion, BRCA1 or BRCA2 gene mutation, or 
history of chest radiation at a young age.3  
However, the National Comprehensive Cancer Network (NCCN) recommends 
that women begin annual screening mammograms at the age of 40 even for women who 
are at average risk. The difference in screening recommendations among various 
organizations is due to differing opinions on the importance of the benefit of 
mammography versus the risks described above.30 The NCCN’s position is that the 
benefit of mammograms outweighs the risk of recall, breast needle biopsy, or over-
diagnosed cancer. Despite controversy on when women should start getting screening 
mammograms and the frequency, all organizations agree that screening mammograms are 
important for breast cancer prevention and early detection.  
Breast Density Overview 
John Wolfe was the first to identify breast density as a risk factor for breast cancer in a 
retrospective study published in 1976.31 As previously mentioned dense breasts are 
considered a moderate risk factor for breast cancer.32 Data from the Breast Cancer 
Surveillance Consortium (BCSC) indicates that women between the ages of 50-64 with 
dense breast have a relative risk (RR) of 1.29 for developing cancer compared to women 
with average density. Women between the ages of  65 to 74 have a RR of 1.30.33 The 
increased risk of for breast cancer due to dense breast is two-fold: breast density 
inherently increases the risk of breast cancer and it makes it difficult to detect lesions on 
mammograms, as will be discussed. Breast density is an established risk factor for all 
breast cancer subtypes, however, the exact mechanism for increased risk is unclear.25,34  
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   Normal breasts are composed of 3 types of tissues: glandular epithelium, fibrous 
connective tissue, and adipose tissue.5 Breast density is determined by the amount of 
fibrous and glandular tissue present in the breasts. 35  
Breast density cannot be determined from a physical exam. Rather, a patient’s 
breast density is determined by visual inspection of a mammogram by a radiologist 
(Figure 1). There are four systems that have been used to classify breast density: Wolfe’s 
grading, Tabar, Breast Imaging Reporting and Data System (BI-RADS), and visual 
estimation. 10 The most common method used in the U.S is BI-RADS, developed by the 
American College of Radiology. The BI-RADS categories for breast density are labeled 
with letters a-d, whereas the BI-RADS assessment categories and management 
recommendations following mammograms are numbered one through six (Table 2). 
There are four categories of breast composition (Table 3) with the last two categories 
falling into what is classified as dense breast.35 When the breasts have differing densities, 
the breast with the higher density is used to categorize breast density. The most recent 
edition of BI-RADS no longer has percentage brackets for the four different breast 
density categories. The committee is awaiting the publication of data using validated 
percentage quartiles before adding it back into the categories.  They are encouraging 
providers to continue using subjective interpretation as they were trained initially.35 
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Figure 1. Example of categories of breast density on mammogram.36 
 
 
 
 
 
 
 
Table 2. BI-RADS Assessment and Management Categories (Adapted from ACR 
BI-RADS Atlas 2013).35 
Assessment Management 
Category 0: Incomplete Recall for additional imaging 
Category 1: Negative Routine mammography screening 
Category 2:  Benign Routine mammography screening 
Category 3: Probably Benign 6-month follow up or continued 
surveillance mammography 
Category 4: Suspicious  Tissue diagnosis needed 
Category 5: Highly suggestive of 
Malignancy 
Tissue diagnosis needed 
Category 6: Known Biopsy-Proven 
Malignancy 
Surgical excision required 
 
Table 3. Breast Composition Categories (Adapted from ACR BI-RADS Atlas 
2013)35 
 
 
 
 
 
Breast Composition Categories 
a. Breasts are almost entirely fatty 
b. Scattered areas of fibroglandular density 
c. Breasts are heterogeneously dense 
d. Breasts are extremely dense 
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Higher degrees of breast density make it more difficult for a radiologist to detect a 
lesion because fatty breast tissue appears radiopaque (black) on an x-ray, whereas fibrous 
or glandular tissue appear radiolucent (white). The increased presence of radiolucent 
areas make it harder to visualize a lesion, since lesions also typically appear white on a 
mammogram.  
Additionally, when a woman’s breast is deemed extremely dense, the sensitivity 
of a mammogram for detecting lesions is significantly decreased.35 Prior research has 
shown that dense breasts decreases the sensitivity of a mammogram from 85.7-88.8% to 
62.2-68.1% in women with extremely dense breasts.31 Breast density also decreases the 
specificity of mammograms from 93.5% to 88.7% for women between the ages of 40-
49.37 Nearly 50% of women fall into the heterogeneously dense or extremely dense 
categories.38  
Breast density itself can be influenced by a variety of factors. It decreases with 
older age and higher body mass index (BMI) and increases with hormone replacement 
therapy.39 A study by the BCSC found that of the estimated 27.6 million women with 
dense breasts about 45% of the women were between the ages of 40-49.37 The same study 
by the BCSC found that only 2 percent of women with a BMI >30 had dense breasts, 40 
percent of women with a BMI between 25.0 to 29.9 had dense breasts, and 58 percent of 
women with a normal BMI had dense breasts.37  Hormone replacement therapy is an 
established risk factor for breast cancer, but is still commonly used for the treatment of 
symptoms in menopause.40 Greendale et al stated that estrogen use alone for 2 years 
resulted in a nonsignificant increase in breast density. Combined hormone replacement 
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with estrogen and progestin resulted in a significant increase of 3-5 percent of breast 
density compared to the placebo and estrogen only groups.41 
 Dense breast may also have an impact on other prognostic factors for breast 
cancer survival. Common tumor prognostic factors include estrogen receptor (ER) status, 
grade, and size.42 Roubidoux et al sought to investigate the relationship between common 
tumor prognostic factors and breast density. The researchers recruited 121 women who 
had negative mammogram results and were later diagnosed with invasive breast cancer.  
Results showed significant findings for age, tumor size, stage, and ER positivity as it 
relates to BI-RADS breast density categories a through d (Table 4 and Table 5). The 
mean age for women decreased as the breast density category increased. The mean size 
of the tumor detected increased as the breast density category increased. The number of 
tumors with estrogen receptor positivity decreased as density increased. Higher degree of 
tumor stage was significantly associated with increased breast density. In conclusion, 
increasing breast density was significantly associated with younger age, larger tumor 
size, higher tumor stage, and negative estrogen receptor status, all of which are negative 
prognostic factors in women who are diagnosed with breast cancer.42  
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Table 4. Tumor Prognostic Factors and Breast Density Category (Adapted from 
Roubidoux et al.)42 
Factor Category 
a 
Category 
b 
Category 
c 
Category 
d 
Overall 
Number 
of 
patients 
15 41 49 16 121 
Mean age 67.8 63.3 58.9 50.4 60.1 
Mean 
Tumor 
size 
(mm) 
11.3 13.0 14.7 19.7 14.7 
Estrogen 
receptor 
positivity 
15 32 37 8 92 
 
Table 5. Tumor Stage and Breast Density Category (Adapted from Roubidoux et 
al)42 
Tumor stage Category a Category b Category c Category d 
I 10 25 28 5 
II 5 16 18 8 
III 0 0 3 2 
IV 0 0 0 1 
 
Breast Density Notification Legislation  
The increased risk of breast cancer and the lower sensitivity of mammograms in women 
with dense breasts has led to changes in legislation by many states in the U.S.43 The 
movement for change was led by Nancy Capello, who was diagnosed with stage IIIC 
breast cancer 6 weeks after being told she had a normal mammogram.9 Prior to her cancer 
diagnosis, she was unaware that she had dense breasts and that it was a risk factor for 
breast cancer. She was shocked that her healthcare providers were familiar with these 
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topics yet never disclosed this information to her, so she began advocating for women in 
Connecticut.  
In 2009, Connecticut was the first state to enact a dense breast notification law 
and there are now 34 states that require some sort of dense breast notification for 
patients.44,45 The goal of DBN legislation is to provide patients with direct notification of 
their mammography findings to increase awareness, which could potentially lead to 
increased discussions with healthcare providers about breast cancer, dense breasts, and 
associated risk factors. 
 In Massachusetts the DBN legislation currently requires the letter to include the 
following information: 1) that dense breast tissue was found on the mammogram; 2) the 
degree of density present with an explanation; 3) that dense breast tissue is a common 
and normal finding but has an associated increased risk of cancer; 4) that the presence of 
dense breast tissue makes it more difficult to find cancer on a mammogram; 5) the 
potential need for additional testing or screening which should be discussed with a 
healthcare provider; 6) that the report of the mammogram has been sent to the referring 
physician and will become a part of the patient’s medical record; and 7) where to find 
additional information.46  
Supplemental Screening  
The need for supplemental screening has been heavily discussed given the increased risk 
for breast cancer and decreased sensitivity and specificity of mammograms for women 
who have been classified as having dense breasts. The supplemental screening options 
 16 
include: ultrasound (US), digital breast tomosynthesis (DBT), MRI, and molecular breast 
imaging.6  
Ultrasound is the most commonly used additional screening method for women 
with dense breast who have had a negative mammogram. US is able to detect 2-4 cancers 
per 1000 screens.6 Some positive aspects of US are that it does not require any radiation 
and costs are similar to screening mammography. However, many imaging centers do not 
offer screening with US. This may due to studies showing that screening with US had 
low specificity and positive predictive values when compared with mammography.6 One 
review found that in women with a high risk for developing breast cancer there is not 
sufficient evidence showing that mammogram with adjunct US was more sensitive than 
mammogram alone. In fact, using US increased the number of false-positive findings 
which led to unnecessary breast biopsies.47 
MRI has been offered to women with an elevated lifetime risk of breast cancer 
over 20 percent.29 The sensitivity and specificity of an MRI are 94.3% and 24.4% 
respectively. MRI is able to detect 14+ cancers per 1000 screens following a 
mammogram. Despite the high sensitivity for detecting cancer, barriers to use of MRI as 
an additional screening method include high cost, concern for side effects from contrast 
injection, and lack of availability. An additional factor limiting MRI use for women with 
dense breast is the lack of randomized control trials comparing the effectives of MRI and 
mammography in women with dense breasts.6 
  Tomosynthesis is a 3-dimensional mammography that reconstructs a 3-d image 
of the breast using multiple thin slices.29 This method of supplemental screening has 
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increased sensitivity and specificity for all breast densities. However, tomosynthesis has 
only been shown to detect 1-2 cancers per 1000 screens following a mammogram.6 While 
all three supplemental screening methods have positive features for the detection of 
breast cancer in women with dense breast, data is still lacking on which method is 
superior.6 Given the lack of conclusive evidence for methods of supplemental screening 
in women with dense breasts there are still no guidelines on how to best guide patients 
who have been diagnosed with dense breasts.37 Some researchers suggest that while there 
are no official guidelines for supplemental screening it should be addressed on a case-by-
case basis while taking into consideration additional risk factors besides breast density.37 
This is concerning given that DBN legislation requires that women be informed of 
additional screening options.  
Existing research 
 Prior to analyzing how DBN legislation has impacted women’s knowledge 
regarding dense breasts, it is important to establish a baseline of knowledge for women 
who have not received a DBN. Manning et al conducted a study in Michigan in 2013 
when at the time only two states, Connecticut and Texas, had mandated reporting.7  
Participants included women who had previously participated in a breast density (BD) 
imaging study with ultrasound. Researchers mailed 236 surveys and they received 77 
responses. Women were asked “Do you know what breast density is?” and responded on 
a scale from 1 (I have never heard about it) to 5 (I know exactly what it is). They were 
also asked if they were aware of the density of their own breast and, if they answered yes, 
they were further prompted to disclose their breast density category. They were asked to 
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define breast density in their own words. Three experts graded the responses on a scale 
from 1 (not correct at all) to 4 (quite accurate for a lay person). Finally, women’s 
knowledge of breast density as a risk factor was assessed using an agreement statement. 
They were asked “Women with more dense breasts are at a greater risk for getting breast 
cancer” and asked to rate this on a scale from 1 (I strongly disagree) to 5 (I strongly 
agree). Results indicated that women generally perceived that they knew what breast 
density was (M= 3.64, SD =1.29). The accuracy of their BD definitions were determined 
to be neither highly accurate nor highly inaccurate (M=2.42, SD = 0.97). Within the 
sample, only 33.8% of women responded that they were aware of their own breast 
density. Women were only slightly aware that breast density was a risk factor for breast 
cancer (M =3.26, SD=1.19).7 The results of this study indicate that though women 
perceive that they know what the definition of dense breast is their definitions are not 
always accurate. Despite possibly knowing the definition of dense breast about two-thirds 
of participants were not aware of their own breast density. This is concerning in that 
knowledge of breast density does not necessarily correlate with personal knowledge of 
one’s own breast density. Given that breast density is an established risk factor for breast 
cancer, it is important for women to not only be aware of breast density as a topic, but to 
also be aware of their personal breast density since it can negatively affect their health.   
Although this study was conducted in a state that did not require DBN legislation, 
it is relevant for discussion in that, despite women’s perceptions of their own knowledge 
about dense breasts, many of them lacked thorough knowledge of the topic. The 
participants did not have the most accurate definitions, were unaware of their own breast 
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density, and were not aware that dense breasts are a risk factor for cancer. Women who 
are currently receiving DBNs may have similar outcomes seen in this study in that, 
though they may be aware of the topic of dense breasts following DBN legislation, their 
knowledge may not be robust enough to make important decisions surrounding their 
health. One limitation of this study is that the participant knowledge was assessed using a 
questionnaire which could have led to a response bias. The order of the questions from 
BD knowledge to BD as a risk factor could have led more participants to answer 
correctly that BD is a risk factor than would have been anticipated.  
 O’Neill et al was one of the first studies that assessed patient awareness of breast 
density as a risk factor and as a personal risk factor in patients who had received a recent 
mammogram with benign results. Participants were between the ages of 35-50, English 
speaking, and with no prior history of cancer or breast abnormality. This study was 
unique in that it included participants who were younger than the recommended age of 
screening of 40 in an attempt to include participants who were potentially receiving an 
early screening exam due to an increased risk of breast cancer. The sample was 
predominantly of white race (68%, 24% African American, 4% Asian American, 2% 
Native American/Pacific Islander, 2% identified as more than one race). 93% of the 
sample identified as non-Latina and only 7% identified as Latina. Results indicated that 
62% of the sample (N=213) were aware of breast density as a risk factor. Of the 213 that 
were aware of breast density as a risk factor and 112 had spoken to a provider about 
breast density. Patient awareness was highest among white women  when compared to all 
other racial groups collectively (OR = 2.22, p < .050), those of older age (OR= 1.07, p < 
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.10), and those with an affected first-degree relative (OR = 4.04, p<.05). One of the 
limitations of this study is that it did not identify how women were aware of the various 
questions associated with breast density. One of the hypotheses was that women were 
likely aware of breast density due to media coverage of DBN legislation in Virginia that 
aired in Washington D.C., where the study was conducted. However, media coverage 
does not guarantee that the DBN legislation served its purpose of increasing breast 
density awareness. Future studies will need to ensure that women have received DBNs as 
part of their inclusion criteria in order to assess the effectiveness of this new legislation 
on awareness and knowledge. Another limitation is that the sample was predominantly 
white, potentially making the study’s conclusions less generalizable.  
In 2016 a study was performed that focused on the content of dense breast 
notifications across 24 states and how well patients understood the letter they received 
about their dense breasts.48 The researchers used the Flesch-Kincaid grade level (range: -
3.4 to no upper bound) and the Dale-Chall readability tests (range: ≤ 4 to ≥16) to assess 
for the level of reading difficulty in the notification. The level of understanding for the 
participants in this study was assessed by the Patient Education Materials Assessment 
Tool (range: 1% to 100%).48 The results of this study showed that the Flesch-Kincaid 
readability levels ranged from grades 7 to 19.4 and all DBNs scored low on patient’s 
ability to understand the content.48 While the recommended reading grade level for DBNs 
is between 7 and 8, this study found the readability levels were higher than this in many 
states. The purpose of DBNs was to increase patient awareness and understanding of 
breast density, but the results of this study indicate that there is still a lack of 
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receptiveness in the content of DBNs. This study highlights the need for methods to 
improve patient understanding whether it be modification of DBNs across the U.S. or 
patient education.     
 Yeh et al. reported on the impact a DBN could potentially have on women. In this 
study, the participants’ perceived risk, anxiety, and intentions for future screening were 
assessed before and after receiving a hypothetical DBN.14 The participants in this study 
were who were recruited did not necessarily have dense breast thus they received a 
hypothetical DBN. The participants were asked to rate their perceived lifetime risk of 
getting breast cancer on a scale from 0 to 100%. The anxiety level among the participants 
was assessed using the Short Form of the Profile of Mood States (POMS-SF).14 Data was 
analyzed using a dependent sample t-test to assess the difference between perceived 
lifetime risk and intention for future screening prior to and after receiving a DBN. The 
results indicated that women reported a greater perceived risk after reading a DBN 
(M=27.82, SE =1.53) than prior to reading a DBN (M= 19.79, SE =1.29), (p<.001, d= 
0.67). The participants also had greater intentions for getting a mammograms after 
reading a DBN (M= 12.17, SE=.30) than prior to reading a DBN (M =11.35, SE=.35), 
t(183)= -3.29, p= .001, d=0.25. The study also showed that higher anxiety levels among 
women resulted in greater perceived risk and stronger intention for additional screening.14 
The results in this study highlight the importance of monitoring anxiety levels in patients 
who receive DBNs since it mediates the relationship of perceived lifetime risk of breast 
cancer and intention for additional screening. One limitation of this study is that the 
women who were included did not necessarily have dense breasts. The impact of actually 
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having dense breasts may increase the effect of receiving a DBN on anxiety level and 
intentions for future screening.  
 Guterbock et al. performed a population survey about dense breasts among 
women in Virginia. DBN legislation in Virginia went into effect in July 2012, a year 
prior to the study, and this study’s goal was to assess what women knew about dense 
breasts following enactment of legislation. Patients were assessed using a questionnaire 
that included questions surrounding: family experience with breast cancer, current breast 
cancer screening practices, participant’s perceived risk for breast cancer, understanding 
of breast density, understanding of current screening guidelines, willingness to change 
screen practices, and where to look for other sources for information.32 The participants 
were asked to list any risk factors that they were aware of for breast cancer and only 0.8% 
listed breast density as a risk factor. 32 When specifically asked about their familiarity 
with breast density,  51.8% of women who had had a mammogram within the year prior 
to the study stated they were informed by a healthcare provider. Virginia only requires 
that women with heterogeneously or extremely dense breast be notified of their breast 
density. 50 percent of woman who receive mammograms fall into these two breast 
density categories, so the results of this study were as expected for women who receive 
DBNs.32 However, among the women who recalled being informed about having dense 
breasts, only 53% of them were aware of the relationship between dense breasts and 
breast cancer.32 The results of this study indicate that DBN legislation seems to be 
slightly effective since more than half of the women in this study were aware of breast 
density, similar to the number of women in the U.S. who have dense breasts. However, 
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awareness of one’s own breast density did not necessarily indicate that patients were 
aware of how breast density affects their personal risk for breast cancer. This highlights 
the need for further interventions to aid with patient education and understanding beyond 
awareness of breast density. A limitation of this study was that the researchers did not 
verify what percentage of participants actually received a DBN. If receiving a DBN 
would have been taken into consideration, it would allow for better analysis of the 
relationship between DBNs and patient understanding of breast density. Another 
weakness is that the survey was conducted in Virginia making the conclusions less 
generalizable across the U.S especially, since DBNs vary from state to state. 
 A similar study to the one conducted by Guterbrock et al. was performed in a 
Massachusetts hospital that serves vulnerable populations. This was a qualitative study to 
assess patients’ perceptions and actual participation in follow-up care, such as discussion 
with a provider or additional screening, after receiving a DBN. 13 Participants (N=58) 
were screened for the following criteria: English speaking women between the ages 40-
75, who had a mammogram at Boston Medical center, and had received a DBN. 
Participants were then asked questions about their DBN and their understanding of the 
content. 81% of the participants recalled receiving the DBN and of this group all recalled 
that the letter informed them that they had dense breasts. However, the amount of recall 
in the content of the letter varied among the participants (Table 5).13 Although all of the 
participants were able to recall that they have dense breasts, many were unable to 
remember that it has increased risk for breast cancer and that it can cause masking on 
mammograms.  This is another study that emphasizes the need for further education 
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beyond just awareness of breast density to include implications for the finding. One 
useful result of this study was that the participants in this study expressed that they 
wished the material had been presented to them in clearer language with less clinical 
jargon and many would have preferred verbal communication of results. The feedback 
from these participants can be used to tailor a more effective method of giving patients 
important information. One strength of this study is that the inclusion criteria required 
that women had received a DBN. This allows for a more accurate analysis of the 
relationship between DBNs and patient understanding of breast density. A limitation of 
this study is that it was conducted at a single hospital with a small sample size making the 
results less generalizable. The women who were included were only English-speaking as 
well.  
 
Table 6. Recall of notification content. (Adapted from Gunn 2018)13 
Content Percent of participants who recalled 
specific information 
Presence of dense breasts 100% 
Increase in breast cancer risk 10% 
Masking bias 28% 
Recommendation to talk to a provider 34% 
Possible benefits of additional screening 31% 
 
 
 Manning et al wanted to assess how knowledge about breast density impacted 
health decision-making. Researchers in this study recruited 67 African Americans and 71 
European-Americans and randomly assigned them to one of four groups: no information, 
only BD information, only imaging modality information, or both BD and imaging 
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modality information. They used the theory of planned behavior (TPB) to measure the 
effect of knowledge about breast density and imaging modalities on breast cancer 
screening decision-making. TPB predicts that knowledge, attitudes, and intentions are 
useful in the prediction of actual behaviors.26   The authors predicted that having 
information about BD and new imaging modalities would increase the women’s intention 
to discuss breast cancer screening with their physician. Researchers used a 2 by 2 full-
factorial MANOVA to examine experimental effects. They found that BD information 
had a significant impact on intentions of having a discussion with a provider about breast 
cancer screening (F1,130 = 14.04, p < .01, η2 = .10).49 One strength of this study is that it 
highlighted the importance of patient education in increasing the frequency of positive 
behaviors. However, the researchers focused on intentions and not actual behaviors, 
which could possibly show different results in real life situations.  
 Prior research has shown that about 50% of primary care providers in states with 
DBNs were aware of breast and density. Casas et al. performed a study on breast health 
providers in an attempt to address the lack of understanding among providers. 
Participants were clinicians who educate women about breast health at Boston Medical 
Center (BMC). Clinicians included were internal medicine providers in primary care, 
internal medicine residents in primary care, and radiology residents. A total of 14 
participants were included in this study In this study, the researchers developed an 
educational workshop that included a sample DBN and a PowerPoint presentation that 
covered topics about breast density. The efficacy of the workshop was assessed by 
surveys prior to the intervention, immediately after the intervention, and 3 months after 
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the intervention. The survey included questions about demographics, practice behavior, 
knowledge about breast density, and attitudes of the participants.50 To assess change in 
knowledge the participants were given 10 questions and then paired t-tests were used to 
analyze scores at following the workshop. The results indicated that participants were 
more knowledgeable about breast density on the postintervention survey (2.00 points, 
p<.0001). At the 3-month follow-up survey, there was no statistically significant change 
from the postintervention score (0.87 points, p=.06). The results of this study 
demonstrated the effectiveness of the workshop at leading to retention of knowledge 
surrounding breast density postintervention and at 3 months. One limitations of this study 
is the small sample size. Another limitation is that retention of information was not 
analyzed past 3 months. While this study provides information on provider knowledge 
and comfort after educational interventions, there is lack of research on patient 
knowledge and comfort after an educational intervention. Given the success of an 
educational intervention on provider knowledge around breast density, it is important to 
assess if similar methods could improve patient knowledge. 
 Prior research has focused on breast density awareness, knowledge, and reactions 
following DBN legislation. Studies have shown that while women may have heard of 
dense breast many are still unsure of what it exactly means and its relationship with 
breast cancer. There have been efforts to improve provider knowledge about breast 
density, which seems to be promising, however, research is lacking on how to improve 
patient’s knowledge. Current legislation in Massachusetts requires that a DBN encourage 
women to speak with their provider for any further questions, however, as studies have 
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shown some providers may still be unfamiliar with this topic. While new research shows 
promising results for provider education interventions it would be helpful to develop 
alternative methods to educate patients about breast density.  
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METHODS 
Study design 
A pretest-posttest design will be used to evaluate the effect of an educational intervention 
on patient awareness, knowledge, and emotions in regards to breast density. Participants 
will attend a 45-minute lecture with educational materials provided about breast density 
followed by a 15-minute question-answer period. The aim of this study is to improve 
patient understanding and comfort surrounding the topic of breast density as it relates to 
breast cancer.  
Study population and sampling 
Individuals who will be invited for participation in this study are women who have had a 
routine screening mammogram at BMC and have received a DBN stating that they have 
either heterogeneous or extremely dense breast. Women will be contacted via phone or 
email after HIPAA waiver authorization has been obtained. The patients eligible for this 
study will be English-speaking women between the ages of 40 to 74 with at least a 5th 
grade reading level who have had a routine screening mammogram at BMC within the 
last year. The age criteria were made in concordance with the screening 
recommendations provided by the USPTF, NCCN, and ACR. Exclusion criteria include: 
1) women with prior diagnosis of breast cancer and 2) previous or current enrollment in a 
breast density awareness study.  
A sample size of 31 participants is needed to have a power of 80% to detect an 
effect size of 0.5 standard deviations in the paired t test at an alpha of 0.05.   
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Intervention 
Participants will meet with a moderator in a lecture room. The intervention in this study 
will be a 1 hour lecture with 45 minutes of teaching followed by a 15 minute question-
answer period. The lecture material provided will be in the format of a PowerPoint 
accompanied by images. The material included will be approved by a knowledgeable 
breast health provider and a radiologist. The goal of this study is to improve patient 
understanding about breast density and decrease anxiety after receiving a DBN letter 
following a screening mammogram.  
 The lecture material will be divided into the following three sections: 1. General 
Information about Breast Density; 2. Breast Density; and Breast Cancer 3. Supplemental 
Screening Recommendations. The subsections included are outlined below. 
Topics  
1. General information about Breast Density (25 minutes) 
a. Normal Breast Composition 
b. Definition of Dense Breasts 
c. Method of identifying Breast density 
d. Categories of Breast Density  
e. Frequency of Dense Breasts  
2. Breast Density and Breast Cancer (10 minutes) 
a. Effect of Breast Density on detecting Breast Cancer 
b. Increased Risk for Breast Cancer 
3. Final Recommendations (10 minutes) 
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a. Tips for discussion with health provider 
i. Personal risk assessment 
ii. Additional Screening options: Tomosynthesis and MRI 
Study variables and measures 
Participants will complete a pre- and postintervention questionnaire in order to determine 
the effects of the educational intervention on knowledge of breast density and anxiety 
level. The preintervention questionnaire will include a question portion about 
demographics including: age, race, ethnicity, highest education level, income, and family 
history of breast cancer  The pre- and posttest questionnaire will be identical in order to 
measure the success of the presentation. There will be 10 questions that address breast 
density knowledge and will cover topics discussed during the 45 minute presentation. 
There is no validated survey for breast density knowledge so the 10 question assessment 
was done to mimic a similar study that was conducted by Casas et al.50 Since there is no 
validated survey researchers will need to pilot the survey used in this study. This will be 
done with patients from BMC who meet the same inclusion criteria as the participants in 
this study. The questions regarding anxiety level of the participants will be included on 
the same questionnaire and are derived from the validated Short Form of the Profile of 
Mood States.28 POMS-SF is a 37 item questionnaire that assesses total mood disturbance 
based on a 5-point Likert Scale from 0 meaning not at all to 4 meaning extremely. Prior 
studies have POMS-SF has comparable accuracy of results as when POMS is used with 
the advantage of POMS-SF taking less time to administer.51 Surveys will be administered 
at 3 months and 6 months postintervention to assess for duration of the intervention. 
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Given that this is a new area of research, there will also be a space provided at the 
end of the postintervention questionnaire for participants to give feedback on the 
presentation and an area for suggestions for improvement. The goal of this question is to 
allow for participant feedback in order to improve patient educational interventions for 
women with dense breasts.  
Recruitment 
Recruitment will take approximately 1 week with the knowledge that about 60 women 
get a mammogram per day at the Belkin Breast Health Center with approximately 50% 
having dense breast and a 20% response rate. The research assistant will obtain a list of 
women who have had a screening mammogram at the Belkin Breast Health Center after a 
HIPAA waiver authorization has been approved. The women will be contacted via phone 
or email and invited to participate in this study. They will be screened with the following 
questions in order to determine eligibility: 1. Have you ever been diagnosed with breast 
cancer?; and 2. Have you ever or are you currently participating in a breast density 
awareness study? After eligibility has been determined the women will be offered an 
opportunity to attend a dense breast lecture with a chance to win a $30 Visa gift card. 
Eligible participants will then be given a date and time to attend the lecture session.  
Data collection 
Participants will be given a questionnaire in multiple choice format prior to the start of 
the lecture. Participants will be asked to write the last 5 digits of their phone number on 
the top of the pre- and post-questionnaire in order to keep the data linked. At the 3 and 6 
month marks participants will receive the questionnaires via the same method of delivery 
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of their DBN. They will also input the 5 digit code on these questionnaires to link them 
with the prior results. The data will then be transferred from the questionnaire onto a 
spreadsheet by an undergraduate assistant.  
The postintervention questionnaire will be given at the conclusion of the question-
answer period. Data will be transferred and stored in the same method described for the 
preintervention questionnaire. However, the open-ended portion of the postintervention 
questionnaire for participant feedback will be transferred onto a word document.   
  
Data analysis 
At the conclusion of the study, the data acquired will be entered into an excel spreadsheet 
or word document as appropriate. For the knowledge based portion of the questionnaire, 
correct answers will be given a score of 1 and an incorrect answer will be given a score of 
zero. The range for knowledge-based score will be from a minimum of 0 to a maximum 
of 10.  Given a sample size of 31 participants and analysis of a continuous variable, a 
paired t-test will be used to evaluate the effectiveness of the educational intervention on 
pre- and post- knowledge scores as well as for pre and post- POMS-SF scores. Total 
mood disturbance will be determined from the POMS-SF by adding all of the items then 
subtracting the vigor/activity subscale. The range for total mood disturbance score is -24 
to 124 with a more positive score reflecting a higher Total Mood Disturbance.   
 The short answer portion of the questionnaire will be logged onto a word 
document and then grouped based on recurring themes. This portion will aid the 
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researchers in tailoring educational interventions to be more effective in the future.  This 
is an important step given there are no other studies similar to one the being conducted. 
Timeline and resources 
The project will require the assistance of a primary investigator, a research assistant, an 
undergraduate student worker, a breast health provider, and a radiologist. The primary 
investigator will be responsible for developing the lecture material this will likely take a 
week. The lecture material will then be approved by both a breast health provider and 
radiologist to ensure accuracy of the data being presented. Following approval of the 
lecture material a lecturer will need to be hired and trained to present the data in the 
PowerPoint. It will most likely take a week for the lecturer to become comfortable with 
the material. The research assistant will be responsible for obtaining a list of potentially 
eligible women from the Belkin Breast Health Center. Both the research and 
undergraduate assistant will be responsible for contacting and scheduling eligible 
participants which will take 8 weeks, as discussed previously.  
Researchers will need access to a Boston University School of Medicine or BMC 
lecture room large enough to hold 31 participants and a lecturer. The lecture room must 
also have a computer, projector, and screen to display the lecture material. The student 
worker will collect the surveys and transfer the data to a spreadsheet or word document 
as appropriate which will be done at the conclusion of each lecture. Data analysis will be 
completed by the primary investigator and research assistant which will likely take a 
week. In conclusion, it will take a total of 14 weeks from recruitment to completion of the 
postintervention data analysis. The study will not officially be complete until the 6 month 
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survey has been collected. Participants will be given 2 weeks to complete the survey at 
the 3 month and 6 month mark. Thus, from initial recruitment to data analysis of the 6 
month survey a total of about 10 months is needed.  
Institutional Review Board 
This study protocol will be submitted to The Boston University Medical Center 
Institutional Review Board for exempt review. The research being conducted in this 
study is the effectiveness of an instructional technique, which falls under exempt 
categories defined by the Common Rule in the Code of Federal Regulations Title 45 Part 
46. This study offers minimal risk to the subjects that will be included.  
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CONCLUSION 
Discussion 
This study has the potential to make a positive impact on women who have been 
classified as having dense breasts on their mammograms. This study would be one of the 
firsts attempts to address the knowledge gap of breast density in patients following 
enactment of DBN legislation. Another strength of this study is that it allows for patient 
feedback in recognition of the need for modifications in educational interventions that are 
better suited for patients.  
While the study could benefit women, it also has several limitations that should be 
considered. First, the sample included may not be generalizable. BMC serves a diverse 
patient population with patients who speak 84 languages, however, the participants in this 
study will be English speaking only. Another possible limitation is sampling bias. 
Participants will be selected nonrandomly and offered a $30 Visa gift card as an 
incentive. Although it would be ideal to have random selection of participants, the 
exclusion criteria of participation in prior or current breast density awareness makes it 
necessary for a researcher to contact the participant for screening. Also, the uncertainty of 
the length of time of recruitment period could negatively impact results. Women who are 
recruited close to the time of the intervention could have greater understanding of breast 
density given recent reading of a DBN which would confound results. Another aspect to 
consider is the method used for assessment of knowledge of breast density. The 10 
questions given for knowledge assessment has not been validated in prior studies. Given 
the study design causal inferences cannot be determined since there was no comparison 
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group. Depending on the results of this study future studies will need to be conducted to 
strengthen the reliability of the findings seen here. A potential study would be one where 
the participants recruited would be divided into intervention and non-intervention groups 
and then administered the same questionnaires as the present study.  
Summary 
In 2015, Massachusetts enacted a law that required radiologists to notify women if they 
had dense breasts on their screening mammogram. This legislation was enacted in an 
effort to increase awareness among women who may have not have known that they had 
dense breasts and that dense breasts is a risk factor for breast cancer. Those in favor of 
this legislation believed that women had the right to know whether they were at an 
increased risk for breast cancer so that they could have the appropriate conversations with 
their providers. Opponents of this legislation were concerned that it would cause 
increased distress among patients, especially considering there were no guidelines in 
place for additional screening for women who do have dense breasts. Regardless, the 
legislation has been in place for a few years and current studies have focused on how 
women are reacting to these notifications. 
 Current studies demonstrate that, although women may be aware of dense breasts, 
many do not know what this finding entails in regards to breast cancer. Additionally, lack 
of complete knowledge about breast density tends to provoke anxiety in women. There 
has been an effort to improve provider knowledge about breast density, however, no such 
research exists for patients. Given the current climate surrounding this topic, this study 
 37 
will attempt to address the knowledge gap for women who have received dense breast 
notifications.  
Public health significance 
This study would be one of the first to offer an educational intervention to women who 
have received a DBN in the state of Massachusetts. It would benefit women by offering 
an opportunity to learn more about breast density and could help alleviate distress that 
can be caused by receiving a DBN. This would allow for more productive conversations 
with healthcare providers drawing attention away from explaining what breast density is 
and putting the focus on whether or not additional screening is necessary. Although there 
are no current guidelines for supplemental screening, researchers have encouraged 
providers to assess the need for additional screening based on a personal risk assessment. 
Personal risk assessment can be a timely and difficult conversation. It would be helpful to 
empower women with knowledge regarding breast density so they can make appropriate 
decisions for their health regarding supplemental screening.     
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